BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28472799)

  • 21. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells.
    Zhang T; Zhang J; You X; Liu Q; Du Y; Gao Y; Shan C; Kong G; Wang Y; Yang X; Ye L; Zhang X
    Hepatology; 2012 Dec; 56(6):2051-9. PubMed ID: 22707013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
    Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
    PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma.
    Wang J; Tang X; Weng W; Qiao Y; Lin J; Liu W; Liu R; Ma L; Yu W; Yu Y; Pan Q; Sun F
    Oncogene; 2015 Nov; 34(47):5781-95. PubMed ID: 25728681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.
    Tschaharganeh DF; Chen X; Latzko P; Malz M; Gaida MM; Felix K; Ladu S; Singer S; Pinna F; Gretz N; Sticht C; Tomasi ML; Delogu S; Evert M; Fan B; Ribback S; Jiang L; Brozzetti S; Bergmann F; Dombrowski F; Schirmacher P; Calvisi DF; Breuhahn K
    Gastroenterology; 2013 Jun; 144(7):1530-1542.e12. PubMed ID: 23419361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA-ATB promotes autophagy by activating Yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma.
    Wang CZ; Yan GX; Dong DS; Xin H; Liu ZY
    World J Gastroenterol; 2019 Sep; 25(35):5310-5322. PubMed ID: 31558875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of Yes-associated protein and its association with clinicopathological features of hepatocellular carcinoma: A meta-analysis.
    Lin C; Hu Z; Lei B; Tang B; Yu H; Qiu X; He S
    Liver Int; 2017 Nov; 37(11):1675-1681. PubMed ID: 28345185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.
    Zhang J; Liu P; Tao J; Wang P; Zhang Y; Song X; Che L; Sumazin P; Ribback S; Kiss A; Schaff Z; Cigliano A; Dombrowski F; Cossu C; Pascale RM; Calvisi DF; Monga SP; Chen X
    Am J Pathol; 2019 May; 189(5):1077-1090. PubMed ID: 30794805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
    Ni X; Tao J; Barbi J; Chen Q; Park BV; Li Z; Zhang N; Lebid A; Ramaswamy A; Wei P; Zheng Y; Zhang X; Wu X; Vignali P; Yang CP; Li H; Pardoll D; Lu L; Pan D; Pan F
    Cancer Discov; 2018 Aug; 8(8):1026-1043. PubMed ID: 29907586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
    Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
    J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer.
    Lo Sardo F; Pulito C; Sacconi A; Korita E; Sudol M; Strano S; Blandino G
    Cancer Lett; 2021 Mar; 500():51-63. PubMed ID: 33296708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. YAP activation is an early event and a potential therapeutic target in liver cancer development.
    Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
    J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
    Ahn EY; Kim JS; Kim GJ; Park YN
    Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma.
    Abou-Shady M; Baer HU; Friess H; Berberat P; Zimmermann A; Graber H; Gold LI; Korc M; Büchler MW
    Am J Surg; 1999 Mar; 177(3):209-15. PubMed ID: 10219856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of human liver cancer.
    Baek JY; Morris SM; Campbell J; Fausto N; Yeh MM; Grady WM
    Int J Cancer; 2010 Sep; 127(5):1060-71. PubMed ID: 20020490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
    Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
    Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway.
    Shu B; Zhou Y; Lei G; Peng Y; Ding C; Li Z; He C
    Cancer Sci; 2024 May; 115(5):1476-1491. PubMed ID: 38475938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NUAK2 is a critical YAP target in liver cancer.
    Yuan WC; Pepe-Mooney B; Galli GG; Dill MT; Huang HT; Hao M; Wang Y; Liang H; Calogero RA; Camargo FD
    Nat Commun; 2018 Nov; 9(1):4834. PubMed ID: 30446657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
    Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
    Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.